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within and between the MTM members and controls were measured (difference-
in-differences (DID) analysis). Results: 2382 patients (MTM group: n= 201, mean 
age= 75,44%male; control group: n= 2181,mean age= 74,48%male) in the diabetes 
cohort and 9751 patients (MTM group: n= 563, mean age= 76,39% male; control 
group: n= 9188, mean age= 75,40% male) in the hypertension cohort were included. 
For patients in diabetes cohort, the MTM group had pre-post increase in PDC by 
5.19% (P= 0.05), while the control group had decrease of 2.82% (P< 0.01) (DID= 8.03%; 
P= 0.003). For patients in hypertension cohort, the MTM group had pre-post 
increase in PDC by 17.33% (P< 0.01), while the control group had increase of 9.64% 
(P< 0.01) (DID= 7.67%; P< 0.01). The PDC finding was confirmed with regression 
analyses with propensity score adjustment showing the MTM groups had a sig-
nificant increase in pre-post PDC for hypertension, as compared with the control 
group, while controlling for baseline characteristics (P= 0.01). ConClusions: This 
study found that the pharmacist-managed MTM program significantly increased 
medication adherence in Medicare MAPD patients with hypertension, as compared 
with a control group.
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objeCtives: Oral Antidiabetics (OAD) have been shown to reduce the risk of mor-
tality, particularly among metformin users, which had risk reductions of 36% for 
cardiovascular-related death and 33-40% for all-cause mortality. However, very few 
studies have assessed adherence to OAD and all-cause mortality. A population-based 
nested case-control study design was used to investigate the relationship between 
adherence to OAD and all-cause mortality among incident users of OAD. Methods: 
Incident OAD users were identified using healthcare databases of residents covered by 
the public drug insurance plan of the Province of Quebec, Canada. Patients initiated 
OAD therapy between 2000 and 2009 and were aged 45-85 years at cohort entry. A 
nested case-control design was conducted to study mortality occurrence. Each case 
was matched to 10 controls by gender, age and duration of follow-up. The adherence 
to OAD was measured by calculating the medication possession ratio. Conditional 
logistic regression models were used to estimate the association between adherence 
to OAD and all-cause mortality adjusting for various potential confounders. Results: 
The cohort included 63,859 incident OAD users at entry: mean age was 68 years old, 
45% were male, 37% had coronary artery disease, 82% had hypertension, and 62% 
dyslipidemia. Most patients initiated their OAD treatment with biguanides (78%) 
and sulfonylureas (12%). The average follow up time was 48 months. Among those 
deemed adherent, the risk of mortality was decreased compared to nonadherent (Rate 
ratio: 0.67 [95%CI 0.64-0.70]). The likelyhood for mortality was higher for patients with 
heart failure (1.56 [1.49-1.65]), ≥ 2 cardiovascular diseases (1.45 [1.39-1.52]), amputa-
tions (2.03 [1.42-2.91]), chronic viral infections (1.73 [1.44-2.07]), corticosteroid use 
(1.69 [1.56-1.89]), and ≥ 1 hospital admissions (1.73 [1.65-1.80]). Conversely, mortality 
was least likely for patients with dyslipidemia (0.76 [0.73-0.79]), and hypertension 
(0.88 [0.83-0.94]). ConClusions: Adherence to OAD seems to be associated with a 
risk reduction of mortality. Further research is needed to confirm this risk. Residual 
confounding may remain a potential issue.
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objeCtives: To assess basal insulin persistence, associated factors, and economic 
outcomes for insulin-naïve people with Type 2 diabetes mellitus (T2DM) in Japan 
using health insurance claims data. Methods: People aged ≥ 18 years diagnosed 
with T2DM with their first claim for basal insulin between 5/2006-4/2013 (index 
date), no insulin use before index date, and continuous insurance coverage for 6 
months before (baseline) and 12 months after index date were selected from the 
Japan Medical Center Database. Based on whether there were ≥ 30 day-gaps in basal 
insulin use, patients were classified as continuers (no gap), interrupters (≥ 1 prescrip-
tion after gap), and discontinuers (no prescription after gap). Multinomial logistic 
regression model was used to identify factors associated with persistence. Annual 
healthcare resource use and costs were compared separately between continuers 
and interrupters, and continuers and discontinuers using propensity score-based 
inverse probability weighting to adjust for baseline differences. Results: Of the 
827 people included in the sample (mean age: 50 years, ~71% male), 36% continued, 
42% interrupted, and 22% discontinued basal insulin therapy in the year after initia-
tion. Inpatient visits and using fewer classes of non-insulin antidiabetic medica-
tions during baseline were associated with higher likelihoods of interrupting or 
discontinuing insulin therapy. Relative to interrupters and discontinuers, continu-
ers had lower hospitalization rates (continuers:12.7%, interrupters:25.4% [p< 0.001], 
discontinuers:28.4% [p< 0.001]) and lower inpatient costs (continuers:JPY132,013, 
interrupters:JPY225,745 [p= 0.054], discontinuers:JPY320,582 [p= 0.036]), but 
higher pharmacy costs (continuers:JPY158,403, interrupters:JPY134,301 [p= 0.039], 
discontinuers:JPY121,593 [p= 0.002]) in the year after insulin initiation. The total 
healthcare costs were similar for the three cohorts. ConClusions: Substantial 
proportions of people with T2DM initiating basal insulin in Japan interrupt or dis-
continue treatment within the year after initiation, and they have higher rates and 
costs of hospitalizations than continuers. Further research is needed to understand 
reasons behind basal insulin persistence and the implications thereof, to help clini-
cians manage T2DM more effectively.
ated over a 60-year horizon, discounted at 3.5% annually. Results: Mean life 
expectancy of 61.4 years and 22.7 (14.1) undiscounted (discounted) QALYs were 
predicted. Maintaining a 1% reduction in HbA1c was associated with an estimated 
gain of 0.54 QALYs per patient. A 3kg weight loss and 30% reduction in frequency 
of symptomatic hypoglycaemic episodes produced a combined QALY gain of 0.38 
(77% attributable to weight loss), whereas the reverse gave a QALY decrement of 
0.87 (93% attributable to weight gain). ConClusions: The beneficial effects of 
improved glycaemic control on QALYs, achieved through the avoidance of diabetes 
related complications, may be offset by characteristic treatment-specific adverse 
effects, such as weight gain and frequency of hypoglycaemia. The comparative 
weight and hypoglycaemic profiles of available therapies are therefore key to both 
their cost-effectiveness and effectiveness in clinical practice.
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objeCtives: Diabetes Mellitus II (DM type II) is characterized by high prevalence 
and severe vascular complications. They are the main cause of disability and death 
in DM patients and lead to grave social and economic consequences. The objective of 
the present study was to assess the impact of selective inhibitors of sodium-glucose 
co-conveyor type 2 on frequency of complications and the costs per QALY compar-
ing with inhibitors dipeptidyl peptidase-4 type. Methods: Modeling using Global 
«Cardiff diabetes model» in time horizon of 25 years. Strategy I: Line I - selective inhibi-
tors of sodium-glucose co-conveyor type 2 (for example, dapagliflozin), Line II - Line I 
+ metformin; Line III: insulin. Strategy II: Line I - inhibitors dipeptidyl peptidase-4 type 
(for example, sitagliptin); Line II - Line I + metformin; Line III: insulin. The direct medi-
cal costs of medicines, out -patients care and fatal complications were evaluated and 
cost utility analysis (CUA) were held. Results: The direct medical costs for Strategy I 
for 1000 patients during 25 years were 5 309 305 USD: for Strategy II - 5 316 676 USD (7 
371 USD higher). The strategy I helps to prevent the 11 fatal complications among 1000 
DM type II patients. Reducing the frequency of complications provide saving 22 523 
USD for cohort during 25 years. Costs per QALY for Strategy I were on 26 UDS less than 
for Strategy II. The results of CUA were proved by sensitivity analysis. ConClusions: 
Present study has shown that selective inhibitors of sodium-glucose co-conveyor 
type 2 is more cost-effective as a first line therapy thanks to reducing the frequency 
of fatal vascular complications and the costs per QALY.
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objeCtives: Hypoglycaemic episodes are a common side-effect of anti-diabetes 
therapy. The impact and associated costs of severe episodes (i.e. episodes that 
the patient is unable to treat themselves) has been extensively reported. There 
is less information about non-severe hypoglycaemic episodes (NSHE). The objec-
tive was to investigate the costs and resource use associated with NSHEs across 
a number of different countries in Europe. Methods: The ‘Hypoglycaemia in 
Insulin Treated patients’ (HIT) study has recently been completed and reported 
for 11 countries across Europe, reporting data from 6,502 patients. Along with data 
on the frequency and impact of NSHE, the study also collected data on resource 
use associated with NSHEs. Data from ten of the countries were utilized, along 
with published, country specific, cost data to calculate an average NSHE cost in 
each country. Resource use differed for different types of diabetes, costs for Type 
1 diabetes (T1D), and Type 2 diabetes (T2D) are reported separately. Results: 
NSHEs required additional blood glucose tests (3.3-8.2). The numbers differed 
depending on country, type of diabetes (T1D:3.3-7.7; T2D: 1.3-8.2) and whether 
the event was diurnal or nocturnal (min: 1.3-3.7; max: 6.2-8.2). Additionally a 
number (T1D: 0% - 16%; T2D: 3% - 23%), highest in Spain and Germany, of NSHEs 
resulted in contact with healthcare professionals. The average cost (per NSHE) to 
the healthcare system was € 4.34 (T1D - range € 2.10 – € 6.80) ; and € 6.20 (T2D - range 
€ 2.10 – € 11.20). ConClusions: NSHEs pose a substantial burden to healthcare 
systems, and society. While individual episodes incur only a small cost, episodes 
are common, and the frequency of NSHEs means that costs for a country can 
be considerable. In addition to this – the patients will often also bear the cost of 
rescue treatments such as a snack or glucose tablets.
DIaBetes/enDocrIne DIsorDers – Patient-reported outcomes & Patient 
Preference studies
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objeCtives: In 2014, the University of Florida College of Pharmacy’s Medication 
Therapy Management (MTM) Communication and Care Center provided an opt-in 
telephone MTM program to eligible Medicare beneficiaries, who were enrolled in 
AvMed Health Plan, a regional Part D plan in Florida. The objective of this study 
was to determine the impact of pharmacist-provided telephone MTM on medica-
tion adherence in elderly patients with hypertension and diabetes. Methods: 
A retrospective analysis using the AvMed Health Plans (Jan 2013-2014 Dec) was 
conducted for Medicare Advantage Prescription Drug (MAPD) plan beneficiaries 
who received at least two oral anti-diabetics (Diabetes Cohort) and oral anti-hyper-
tensives (Hypertension Cohort), respectively. Adherence, defined by proportion 
of days covered (PDC), was measured using incurred drug claims 6-month before 
and after the MTM program was implemented. Pre-post differences in the PDC 
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treatment. In type 2 diabetic patients, 35 % stopped insulin glargine and 38 % insulin 
detemir. In only 15% of the patients discontinuing the initiated basal insulin, death 
or switch to other insulin or GLP-1RA explained the discontinuation suggesting non-
adherence to insulin therapy from other reasons. ConClusions: There is a consider-
able proportion of diabetic patients discontinuing their initiated basal insulin analog. 
Future studies are warranted to examine the detailed reasons for discontinuation.
PDB85
PotentIal BarrIers to InsulIn IntensIfIcatIon among PatIents WIth 
tyPe 2 DIaBetes: the PatIent PersPectIve In germany
Bøgelund M1, Vega-Hernandez G2, Seitz L3, Cel M3
1Incentive, Holte, Denmark, 2Novo Nordisk Ltd., Gatwick, UK, 3Novo Nordisk Pharma GmbH, 
Mainz, Germany
objeCtives: Patient perceived barriers to intensifying treatment may lead to sub-
optimal glycaemic control. This study assessed patient experience with insulin in 
Germany, preferences on insulin injection, and behaviours associated with inten-
sification in insulin-treated type 2 diabetes mellitus (T2DM) patients. Methods: 
Adults with T2DM diagnosed > 6 months ago and receiving insulin for ≥ 3 months 
were recruited through a representative online panel in Germany. Data were col-
lected via an online questionnaire. Results: Of the 302 respondents, mean age 
was 56 years, with average 12 years since diagnosis and 7 years on insulin. Only 
82% (247/302) knew their HbA1c with 37% (111/302) reporting HbA1c> 8.0%. Overall, 
87% (263/302) had BMI≥ 25kg/m2, with 56% (169/302) BMI≥ 30. Basal-only insulin was 
used by 32% (96/302), short-acting (bolus) insulin only 13% (38/302), basal-bolus 47% 
(142/302), premix 7% (22/302). A total of 72% (216/302) reported ever having a non-
severe (self-managed) hypoglycaemic event with 19% (42/216) of these reporting 
events occurring once-a-week or more. Also, 19% (57/302) reported at some point 
having a severe (requiring help to manage) hypoglycaemic event. 67% (201/302) 
respondents tested blood glucose 3-6 times daily. 12% (11/96) of the basal-only 
respondents had previously received basal-bolus but returned to long-acting insulin 
due to various issues. A total of 51% (49/96) currently on basal-only would hesitate 
to some degree if asked by their physician about intensifying treatment (switch to 
basal-bolus or premix). Most frequent reason was number of daily injections (39%, 
19/49), followed by dose calculation and timing (37%, both 18/49), risk of hypoglycae-
mia (35%, 17/49) and weight gain (33%, 16/49). ConClusions: Number and timing 
of injections, dose calculation, risk of hypoglycaemia and weight gain may present 
barriers to insulin intensification among T2DM patients on basal insulin in Germany, 
and contribute to suboptimal HbA1c control. Therapies addressing these challenges 
may help to achieve treatment goals.
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objeCtives: Factors other than efficacy and safety may influence choice 
of treatment for the patient. Barriers to intensification may lead to poor 
glycaemic control. This study aimed to assess patient barriers and behaviours 
relating to intensification of treatment in insulin-treated Type-2-diabetes (T2DM) 
in the Netherlands. Methods: Patients diagnosed > 6 months ago and receiving 
insulin for ≥ 3 months were recruited through a representative online panel in 
the Netherlands. Data were collected using a web-based questionnaire. Results: 
The 315 respondents had mean age of 59 years, BMI 31kg/m2 and 8-years insulin 
treatment. Of the 179 who knew their HbA1c, 45 (25.1%) were uncontrolled (> 8%) 
with mean HbA1c 9.7%. Overall, basal-only insulin was used by 31.1% (98/315), 
with 6.7% (21/315) on short-acting only (bolus), 47.9% (151/315) basal-bolus, 11.8% 
(37/315) premix and 2.5% (8/315) other. Of the respondents whose main contact 
was primary care, only 17.2% (10/58) of basal-only patients reported ever attend-
ing secondary care for treatment, compared with 32.3% (20/62) on basal-bolus. 
Compared to those on basal-only, more respondents on basal-bolus stated they 
sometimes forget to take insulin (17.3% (17/98) vs 31.1% (47/151), respectively) 
or were likely to forget to pack insulin when travelling or leaving home (6.1% 
(6/98) vs 17.9% (27/151)). If asked by their physician, 41% of basal-only patients 
would hesitate to intensify treatment through adding bolus/switching to premix. 
Most frequent reason was increased number of daily injections (45.0%, 18/40), as 
well as difficulty calculating mealtime dose and risk of weight gain (both 40.0%; 
16/40), timing of dosing with meals (37.5%; 15/40) and hypoglycaemia risk (30.0%; 
12/40). ConClusions: Patients on intensified regimens may require increase 
used of secondary care, whilst number/timing of injections, dose calculation, 
hypoglycaemia risk and weight gain are barriers to insulin intensification among 
T2DM patients on basal insulin. Therapies addressing these may help to achieve 
treatment goals.
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objeCtives: The progressive nature of Type-2 diabetes mellitus (T2DM) requires 
periodic intensification of therapy. Understanding the potential barriers to this 
from patients will support appropriate treatment selection. This study aimed to 
assess hypoglycaemic events, treatment convenience and potential barriers to treat-
ment intensification in Italy. Methods: A web-based survey of subjects with type 
2 diabetes, diagnosed > 6 months previously and receiving insulin for ≥ 3 months, 
recruited via a representative online panel. Results: 302 patients were recruited. 
Mean body mass index (BMI) was 27 kg/m2, with 24% (72/302) BMI> 30kg/m2. Of the 
218 reporting exact HbA1c, 75 (34%) had HbA1c> 8.0%. Of the 72 with BMI> 30kg/m2 
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objeCtives: Studies indicate that poor adherence and low persistence to treat-
ment could lead in not achieving recommended glycemic goals in T2DM patients. 
The aim of this study was to assess the adherence and persistence of patients 
who initiate treatment with insulin or with glucagon-like peptides analogs (GLP-
1) in Spain. Methods: Observational, retrospective study based (funded by GSK) 
on review of medical records from patients located in Badalona sanitary area (1 
hospital and 6 primary care centers). Inclusion criteria: patients ≥ 20 years old 
who initiated treatment with insulin or GLP-1 during 2010-2012, T2DM diagnosis 
at least one year before initiation of injectable treatment. Patients were followed 
for one year. Adherence and persistence during the follow up period were ana-
lyzed. Medication Possession Ratio (MPR) was used as a proxy of adherence. MPR 
is calculated as the percentage of days covered by the medication prescribed 
during the study period. Persistence rate is defined as percentage of patients 
having prescriptions of the ongoing therapy continuously renewed without a gap 
of more than 30 days. Results: 1,301 patients were recruited, mean age was 67.6 
years, 51.6% men, 935 initiated with insulin and 366 with GLP-1. In comparison 
with insulin, patients treated with GLP-1 showed higher adherence to treatment 
(88.1% vs 82.7%; p< 0.001). Higher persistence is also achieved with GLP-1 vs insu-
lin (62.0% vs 55.9%; p= 0.046). After 3 months treatment persistence rate start 
to diverge and differences are maintained during the study period (6 months, 
persistence rate 86.1% for GLP-1 vs 79.4% for insulin; 10 months 77.1% vs 70.8%, 
respectively) ConClusions: Adherence and persistence to treatment seems to 
be higher with GLP-1 than insulin in T2DM patients in Spain. Further studies are 
needed to identify reasons for those differences between treatments. The overall 
management of T2DM should address adherence and persistence as key drivers 
for achieving therapeutic goals.
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objeCtives: Medication adherence and satisfaction with treatment are key 
dimensions of healthcare quality. Large proportion of patients with type 2 dia-
betes mellitus (T2DM) receive oral combination therapy. We aimed to assess 
medication adherence and treatment satisfaction in T2DM patients receiving 
oral combination therapy in a real-world setting. Methods: 160 T2DM patients 
receiving combination therapy for at least 6 months (mean 6.5 yrs, 0.6–17 yrs) 
were enrolled in the multicenter real-world study: cohort 1 – vildagliptin plus 
metformin (mean age 59.6 yrs; male/female 25/57); cohort 2 – sulfonylurea (SU) 
plus metformin (mean age 65.1 yrs; male/female 23/55). All the patients com-
pleted the Morisky Medication Adherence Scale (MMAS 4) and the checklist for 
assessment of treatment satisfaction. Statistical analysis was made using t-test 
and χ 2 criterion. Results: As a whole, 90% patients had good adherence with 
treatment; 50% in cohort 1 vs 36% in cohort 2 were completely adhered with 
medication. Treatment satisfaction was high-rated by the patients; there were no 
patients who were extremely dissatisfied with treatment. All aspects of treatment 
satisfaction – overall treatment satisfaction (0.82 vs 0.54), treatment efficacy (0.98 
vs 0.58), treatment convenience (0.8 vs 0.54) and coping with hypoglycemia (1.06 
vs 0.63) were significantly lower in cohort 2 as compared to cohort 1 (p< 0.02). In 
addition, 59% patients in cohort 2 experienced hypoglycemia vs 28% from those 
in cohort 1. The proportion of patients with better coping with hypoglycemia was 
higher in cohort 1 than in cohort 2 (53.7% vs 31.2; p< 0.006). ConClusions: In 
general, good levels of medication adherence and treatment satisfaction in T2DM 
patients receiving oral combination therapy were demonstrated in a real-world 
setting. Combination of vildagliptin plus metformin was more preferable from 
patients’ perspective in terms of medication adherence and treatment satisfaction 
as compared to SU plus metformin.
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objeCtives: Poor medication adherence is common in diabetes potentially causing 
poor health outcomes and complications. The aim of this study was to analyze the 
discontinuation rate of initiated basal insulin analog in type 1 and type 2 diabetic 
patients in Finland. Methods: The data was obtained from the national reimburse-
ment registry. Study population consisted of 14 462 diabetic patients (18% had type 
1 diabetes) who started basal insulin analogs (insulin glargine or insulin detemir) in 
2012. Patients were followed by their insulin purchases for 18 months after the ini-
tiation. The data was analysed with χ 2-test and logistic regression analysis. Logistic 
regression analysis was used to find out what variables (age, gender, type of diabetes, 
type of insulin analog) explain patient staying in the treatment. Results: Type of 
insulin, gender, age and type of diabetes had statistically significant influence on 
patients’ treatment adherence (p < 0.001 for all). Overall 47 % of patients starting 
insulin detemir and 39 % starting insulin glargine patients discontinued their basal 
insulin treatment within 18 months of the initiation. Most of the patients stopped 
treatment within first 6 months after the initiation. In type 1 diabetic patients, 42 % 
of insulin glargine patients and 57 % of insulin detemir patients stopped the initiated 
